Affidea has signed an agreement to acquire two advanced diagnostic centres from Alliance Medical in central London. The move strengthens the pan-European provider's footprint in one of Europe's largest private healthcare markets.

The targeted sites are located in Harley Street and Marylebone. Subject to customary completion conditions, the transaction is expected to close at the end of October 2026. Until then, the centres will continue operating under the Alliance Medical brand.

Strategic expansion in the UK

This acquisition complements Affidea’s existing UK operations, which include the Fortius Clinic acquired in 2021 and a forthcoming flagship clinic at Wimbledon Quarter. The group also maintains a partnership with London International Patient Services (LIPS Healthcare) for a 40,000 sq ft clinic on Prince of Wales Drive, scheduled to break ground later this year.

Barry Downes, CEO of Affidea UK & Ireland, stated that the acquisition enables Affidea to bring its European expertise in advanced diagnostics to a recognised healthcare destination. The integration aims to complement existing facilities while maintaining continuity of care for patients and referring clinicians.

Operational details and network impact

Following completion, the Harley Street and Marylebone centres will be rebranded as Affidea. Patients will gain access to Affidea’s broader clinical expertise, digital capabilities, and integrated network of healthcare services. The strategy focuses on building an integrated network of community-based clinics and specialised services to enable faster diagnosis and seamless patient pathways.

Ed Matthews, Managing Director of Alliance Medical UK, confirmed that Alliance Medical remains active in the London market. It continues to work with leading NHS Trusts to deliver molecular and diagnostic imaging services, including isotopes and scanning support at various NHS centres across the capital.

What the Numbers Show

The data highlights Affidea’s scale relative to this specific transaction. With over 15 million annual patient visits across approximately 450 centres, the addition of two high-profile London sites represents a targeted geographic densification rather than a volume-driven expansion. This aligns with the company’s stated strategy of combining targeted acquisitions with new facility investments to meet demand for accessible, high-quality care in key urban markets.